Abstract
Acquired and intrinsic multidrug resistance is the major reason for the failure of anticancer chemotherapy. The most important component of clinical multidrug resistance is mediated by P-glycoprotein (Pgp), an ABC transporter encoded by the MDR1 gene and expressed on the membrane of tumor and normal cells. Sensitive and reproducible detection of Pgp expression and function are critical for the development of new MDR1 drugs and clinical protocols aimed at modulating Pgp-mediated multidrug resistance. The most commonly used methods for detecting Pgp distribution and functional activity have major flaws when used in routine clinical diagnostics. In this chapter, we describe and compare these techniques and introduce a new method for simultaneous detection of Pgp expression and function—the UIC2 Shift assay.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Roninson, I. B. (ed). (1990) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, New York.
Gottesman, M. M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385–427.
Lehnert, M. (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer 32A, 912–920.
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361–398.
Higgins, C. F. (1992) ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8, 67–113.
Klein, I., Sarkadi, B., and Varadi, A. (1999) An inventory of the human ABC proteins. Biochim. Biophys. Acta. 1461, 237–262.
Borst, P., Zeker, N., and van Helvoort, A. (2000) ABC transporters in lipid transport. Biochim. Biophys. Acta. 1486, 128–144.
Sikic, B. (1999) New approaches in cancer treatment. Ann. Oncol. 10, 149–153.
Cordon-Cardo, C., O’Brien, J. P., Boccia, J., Bertino, J. R., and Melamed, M. R. (1990) Expression of a multidrug resistance gene product (P-glycoprotein) in human normal and human tissues. J. Histochem. Cytochem. 38, 1277–1287.
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. (1987) Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Nail. Acad. Sci. USA 84, 7735–7738.
Chaudhary, P. M., Mechetner, E. B., and Roninson, I. B. (1992) Expression and activity of the multidrug resistance p-glycoprotein in human preipheral blood lymphocytes. Blood 80, 2735–2739.
Chaudhary, P. M. and Roninson, I. B. (1991) Expression and activity of P-glycoprotein, multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85–94.
Schinkel, A. H., Smit, J. M., van Tellingen, O., et al. (1994) Disruption of the mouse mdr 1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491–502.
Ueda, K., Okamura, N., Hirai, M., et al. (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but no progesterone. J. Biol. Chem. 34 24,248–24,252.
Ernest, S. and Bello-Reuss, E. (1999) Secretion of platelet-activating factor is mediated by MDR1 P-glycorpotein in cultured human mesangial cells. I. Am. Soc. Nephrol. 10, 2306–2313.
Ernest, S. and Bello-Reuss, E. (1998) P-glycorpotein functions and substrates: possible role of MDR1 gene in the kidney. Kidney Int. Suppl. 65, 11–17.
Valverde, M. A., Diaz, M., Sepulveda, F V., Gill, D. R., Hyde, S. C., and Higgins, C. F. (1992) Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355, 830–833.
Roepe, P. D. (2000) What is the precise role of human MDR1 protein in chemotherapeutic drug resistance? Curr. Pharm. Des. 6, 241–260.
Sonneveld, P. (2000) Multidrug resistance in haematological malignancies. J. Intern. Med. 247, 521–534.
Robert, J. (1999) Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur. J. Clin. Invest. 29, 536–545.
Mechetner, E., Kyshtoobayeva, A., Zonis, S., et al. (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 4, 389–398.
Trock, B. J., Leonessa, F., and Clarke, R. (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 89, 917–931.
van den Heuvel-Eibrink, M. M., Wiemer, E. A., de Boevere, M. J., et al. (2001) MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. Leukemia 15, 398–405.
Bradshaw, D. M. and Arceci, R. J. (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 16, 3674–3690.
Beck, W. T., Grogan, T. M., Willman, C. L., et al. (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 56, 3010–3020.
Liu, B., Sun, D., Xia, W., Hung, M. C., and Yu, D. (1997) Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J. Natl. Cancer Inst. 89, 1524–1529.
Chan, H. S. and Ling, V. (1997) Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications. J. Natl. Cancer Inst. 89, 1473–1476.
Rao, V. V., Anthony, D. C., and Piwnica-Worms, D. (1995) Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J. Histochem. Cytochem. 43, 1187–1192.
Bailly, J. D., Muller, C., Jaffrezou, J. P., et al. (1995) Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 9, 799–807.
Leith, C. P., Chen, I. M., Kopecky, K. J., et al. (1995) Correlation of multidrug resistance (MDRl) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/effluxcases. Blood 86, 2329–2342.
Ferry, D. R. (1998) Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int. J. Clin. Pharmacol. Ther. 36, 29–40.
Zaman, G. J., Hens, M. J., van Leusden, M. R., et al. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91, 8822–8826.
Mechetner, E. B. and Roninson, I. B. (1992) Efficient inhibition of P-glycoproteinmediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA 89, 5824–5828.
Mechetner, E. B., Schott, B., Morse, B. S., et al. (1997) P-glycoprotein function involves conformation transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. USA 94, 12,908–12,913.
Park, S. W., Lomri, N., Simeoni, L. A., Fruehauf, J. P., and Mechetner, E. (2003) Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A. 53, 67–78.
Mechetner, E., Tee, L., Park, S., and Fruehauf, J. P. (1998) The UIC2 Shift Assay: improved detection of MDR1 in human tumors based on conformational transitions of functional P-glycoprotein. Proceedings of the American Association for Cancer Research Meeting, New Orleans, LA, 1998.
Mechetner, E., Tee, L., and Fruehauf, J. P. (1999) The UIC2 Shift Assay detects functional P-glycoprotein in tumors and correlates with in vitro drug response to doxorubicin. Proceedings of the American Association for Cancer Research Meeting, Philadelphia, PA, 1999.
Kobayashi, H., Takemura, Y., Miyachi, H. (2001) Novel approaches to reversing anticancer drug resistance using gene-specific therapeutics. Hum. Cell. 14, 172–184.
Mechetner, E., Tee, L., Pavich, D., et al. (1998) High throughput screening for Mdrl substrate specificity using the MDR1 Shift™Assay. Proceedings of the American Association for Cancer Research Meeting, New Orleans, LA, 1998.
Jansen, W. J., Hulscher, T. M., van Ark-Otte, J., Giaccone, G., Pinedo, H. M., and Boven, E. (1998) CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br. J. Cancer 77, 359–365.
Hoki, Y., Fujimori, A., and Pommier, Y. (1997) Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 40, 433–438.
Robey, R., Bakke, S., Stein, W., et al. (1999) Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93, 306–314.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Mechetner, E. (2007). Detection of the MDR1 P-Glycoprotein Expression and Function. In: Albitar, M. (eds) Monoclonal Antibodies. Methods in Molecular Biology, vol 378. Humana Press. https://doi.org/10.1007/978-1-59745-323-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-59745-323-3_13
Publisher Name: Humana Press
Print ISBN: 978-1-58829-567-5
Online ISBN: 978-1-59745-323-3
eBook Packages: Springer Protocols